术前长期使用SGLT2抑制剂患者的术后结局
IMPORTANCE: Case reports and small retrospective studies have suggested that there is an increased risk of postoperative euglycemic ketoacidosis (eKA) and acute kidney injury (AKI) among patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively.…
要点
- 术前长期使用SGLT2抑制剂与术后正常血糖性酮症酸中毒风险轻度升高相关(OR 1.11)。
- SGLT2抑制剂使用者围术期急性肾损伤风险降低(OR 0.69)。
- 使用者30天死亡率低于对照(1.1% vs 1.6%,OR 0.70)。
核心结论
- 术前长期使用SGLT2抑制剂的患者术后正常血糖性酮症酸中毒风险小幅但显著升高,术后急性肾损伤与30天死亡风险则降低。
主要发现
- SGLT2抑制剂使用与术后正常血糖性酮症酸中毒风险升高相关(OR 1.11;95%CI 1.05-1.17)。
- SGLT2抑制剂使用与围术期急性肾损伤风险降低相关(OR 0.69;95%CI 0.62-0.78)。
- SGLT2抑制剂使用与30天死亡风险降低相关(OR 0.70;95%CI 0.55-0.88);30天死亡率使用者为1.1%,对照为1.6%。
- 出现正常血糖性酮症酸中毒的患者中位住院时间延长3天(伴eKA者中位6天,IQR 3-10天;不伴eKA者中位3天,IQR 2-6天)。
关键数值与推荐
- 长期使用SGLT2抑制剂的定义:依据退伍军人健康事务医疗系统药房登记,门诊处方取药超过3次,或末次取药间隔小于180天。
- 主要结局为SGLT2抑制剂使用者与对照的术后正常血糖性酮症酸中毒发生率,次要结局为术后急性肾损伤与30天死亡率。
临床怎么用
- 普通外科医生在术前评估长期服用SGLT2抑制剂的患者时,应警惕术后正常血糖性酮症酸中毒风险,同时认识到该类用药与急性肾损伤及30天死亡风险降低相关。
- 围术期管理中需结合患者个体情况权衡停药与继续用药的利弊,并关注术后酮症酸中毒的监测。
局限性
- 研究对象以男性退伍军人为主,结果外推至其他人群需谨慎。
- 为回顾性病例对照设计,可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Case reports and small retrospective studies have suggested that there is an increased risk of postoperative euglycemic ketoacidosis (eKA) and acute kidney injury (AKI) among patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively. However, there has not been a representative assessment of the risks of these agents among patients undergoing surgery. OBJECTIVE: To evaluate the risk of postoperative eKA, AKI, and mortality within 30 days after surgery among preoperative long-term SGLT2i users compared with nonusers. DESIGN, SETTINGS, AND PARTICIPANTS: This is a multicenter, propensity-matched, retrospective case-control study from the Veterans Affairs Health Care System (VAHCS) National Registry performed from January 1, 2014, to December 31, 2022. Adult patients using SGLT2i preoperatively who underwent inpatient surgical procedures were compared with a 1:5 matched control group using propensity score matching, including the patient's demographic characteristics, comorbidities, and surgical characteristics. Data analysis was performed from June 2023 to August 2024. EXPOSURE: Long-term use of SGLT2i, defined as having more than 3 fills of outpatient prescription or less than a 180-day gap of the last fill according to the VAHCS pharmacy registries. MAIN OUTCOMES AND MEASURES: The primary outcome was the rate of postoperative eKA among SGLT2i users vs control patients. Secondary outcomes included postoperative AKI and 30-day mortality after surgery. RESULTS: Among 462 968 patients undergoing surgery, 7448 SGLT2i users (mean [SD] age, 67.7 [8.1] years; 7204 [96.7%] male) and 455 520 nonusers (mean [SD] age, 65.8 [11.0] years; 424 785 [93.3%] male) were identified. After propensity score matching, 7439 patients were identified as SGLT2i users and compared with 33 489 control patients. SGLT2i use was associated with an increased risk of eKA (odds ratio [OR], 1.11; 95% CI, 1.05-1.17) but reduced risks of perioperative AKI (OR, 0.69; 95% CI, 0.62-0.78) and 30-day mortality (OR, 0.70; 95% CI, 0.55-0.88). The mortality rate 30 days after surgery was 1.1% among SGLT2i users vs 1.6% among control patients. The median hospital length of stay among the patients presenting with eKA increased by 3 days (median [IQR], 6 [3-10] days for those with eKA vs 3 [2-6] days for those without eKA). CONCLUSIONS AND RELEVANCE: Patients treated with SGLT2i had a small but significantly higher risk of postoperative eKA but lower risks of postoperative AKI and 30-day mortality.
引用
- Tallarico RT, Jing B, Lu K, et al. Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users. JAMA Surg. 2025. PMID: 40305034. doi:10.1001/jamasurg.2025.0940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。